



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Product Information

<b>Description:</b>	Anti-CD19-Anti-CD3 IgG format bispecific antibody is a purified recombinant human bispecific antibody with T cell Engager. This bispecific antibody has been tested for specific activity in the functional reporter assay using NFAT-luc reporter Jurkat cell line (BPS Bioscience #60621) in the presence of CD19-CHO cells (BPS Bioscience #79561-H) that overexpress CD19.
<b>Construct:</b>	Anti-CD19-Heavy and Light Chains, Anti CD3-Heavy and Light Chains
<b>Concentration:</b>	1.95 mg/ml
<b>Species:</b>	Human
<b>Formulated In:</b>	8 mM phosphate, 110 mM NaCl, 2.2 mM KCl, pH 7.4, and 20% glycerol
<b>Expression System:</b>	Co-expressed in HEK293
<b>Purification:</b>	Protein A affinity purification of the IgG-tag protein from HEK293 cells.
<b>Format:</b>	Aqueous buffer solution
<b>Stability:</b>	At least 12 months at -80°C. Avoid freeze/thaw cycles.
<b>Storage:</b>	-80°C
<b>MW:</b>	Heavy Chain: 50 kDa; Light Chain: 24 kDa
<b>Purity:</b>	≥90%
<b>Assay Conditions:</b>	<i>Experimental design and assay protocol for measuring anti CD19-anti CD3 functional activity using NFAT-luc reporter Jurkat cell line:</i>


Jurkat effector cells with endogenous TCR/CD3 and transfected reporter NFAT-luc (BPS Bioscience #60621) are incubated with increasing concentrations of anti-CD19 x anti-CD3 bispecific antibody in the presence of CD19-CHO cells (BPS Bioscience #79561-H) or CHO cells (ATCC #CCL-61™).

1. Seed CHO and CD19-CHO cells at 30,000 cells/well and allow a few hours for the cells to attach in a 96-well clear bottom white plate.
2. Seed Jurkat cells at 30,000 cells/well.
3. Add the bispecific antibody at a recommended dilution range of 100 fM-100 nM. The bispecific antibody simultaneously binds to TCR/CD3 on the NFAT-luc Jurkat reporter cells and tumor antigen CD19 on CD19-CHO cells.
4. After 16 hours the luciferase activity is measured using ONE-Step™ luciferase assay (BPS Bioscience #60690) per recommended protocol. The bispecific antibody interaction stimulates NFAT-luciferase activity.


**Applications:** This product is for research use only. It is not suitable for human diagnostic or therapeutic use. The anti-CD19-anti-CD3 IgG format bispecific antibody can be used for studying CD19+ cancer cell-mediated T cell activation, using either primary T cells or reporter cell lines such as NFAT-luc-Jurkat cells (BPS Bioscience #60621).

## Quality Control Data

### 4-20% SDS-Page Coomassie Staining



### Activation of NFAT-Jurkat Reporter cells by Anti-CD19-Anti-CD3 IgG in the presence of CD19-CHO cells



EC50= 27pM

### Related Products:

<i>Products</i>	<i>Catalog #</i>	<i>Size</i>
NFAT Reporter (Luc) – Jurkat Cell Line	<a href="#">60621</a>	2 vials
CD19 CHO Cell Line (High Expression)	<a href="#">79561-H</a>	2 vials
ONE-Step™ Luciferase Assay System	<a href="#">60690</a>	Multiple Sizes
Anti CD19 Antibody	<a href="#">100981</a>	Multiple Sizes
Anti-BCMA-Anti-CD3 Bispecific Antibody	<a href="#">100689</a>	Multiple Sizes
Anti-CD19-Anti-CD3 Bispecific Antibody	<a href="#">100441</a>	50 µg
Anti-BCMA-Anti-CD19-Anti-CD3-His Trispecific Antibody	<a href="#">100761</a>	50 µg
Anti-CD19 CAR / NFAT (Luciferase) Reporter Jurkat Cell Line	<a href="#">79853</a>	2 vials